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Introduction: The POU class 1 homeobox 1 transcription factor (POU1F1, also known as Pit-1) is expressed in the
mammary gland and its overexpression induces profound phenotypic changes in proteins involved in cell proliferation,
apoptosis, and invasion. Patients with breast cancer and elevated expression of Pit-1 show a positive correlation with
the occurrence of distant metastasis. In this study we evaluate the relationship between Pit-1 and two collagenases:
matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-13 (MMP-13), which have been related to metastasis
in breast cancer.
Methods: We began by transfecting the MCF-7 and MDA-MB-231 human breast adenocarcinoma cell lines with the
Pit-1 overexpression vector (pRSV-hPit-1). Afterward, the mRNA, protein, and transcriptional regulation of both MMP-1
and MMP-13 were evaluated by real-time PCR, Western blot, chromatin immunoprecipitation (ChIP), and luciferase
reporter assays. We also evaluated Pit-1 overexpression with MMP-1 and MMP-13 knockdown in a severe combined
immunodeficiency (SCID) mouse tumor xenograft model. Finally, by immunohistochemistry we correlated Pit-1 with
MMP-1 and MMP-13 protein expression in 110 human breast tumors samples.
Results: Our data show that Pit-1 increases mRNA and protein of both MMP-1 and MMP-13 through direct transcriptional
regulation. In SCID mice, knockdown of MMP-13 completely blocked lung metastasis in Pit-1-overexpressing MCF-7 cells
injected into the mammary fat pad. In breast cancer patients, expression of Pit-1 was found to be positively correlated
with the presence of both MMP-1 and MMP-13.
Conclusions: Our data indicates that Pit-1 regulates MMP-1 and MMP-13, and that inhibition of MMP-13 blocked
invasiveness to lung in Pit-1-overexpressed breast cancer cells.Introduction
To develop metastasis, breast cancer cells need, among
other steps, to break their intercellular adhesion complexes
and basement membrane to acquire motility to invade ad-
jacent tissues [1]. Proteolytic enzymes of various classes
(metallo, aspartic, cysteine, serine, and threonine) execute
the breaking down of matrix elements. However, some
components, particularly the interstitial collagens, are
very resistant to proteolytic attacks, being degraded only
by matrix metalloproteinases (MMPs) [2]. MMPs are* Correspondence: roman.perez.fernandez@usc.es
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unless otherwise stated.synthesized as inactive zymogens, which are then activated
predominantly pericellularly by either other MMPs or
serine proteases. MMPs’ activity is specifically inhibited
by the so-called tissue inhibitors of metalloproteases
(TIMPs). Interstitial collagenases are a subfamily of MMPs
that cleaves the stromal collagens. This subfamily includes,
among others, collagenase 1 (MMP-1), and collagenase 3
(MMP-13). MMP-1 is the most ubiquitously expressed of
the interstitial collagenases. It is produced by a wide variety
of normal cells, for example, stromal fibroblasts, macro-
phages, endothelial cells, and epithelial cells, as well as by
numerous tumors [3]. MMP-1 is often upregulated in
breast cancer, especially in basal-type tumors [4], and seems
to be critically involved in metastatic dissemination [5,6].
Moreover, it has been suggested that MMP-1 is associatedentral. This is an Open Access article distributed under the terms of the Creative
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in breast cancer [4]. Human collagenase-3 (MMP-13) was
first identified in breast carcinoma [8-10]. Nielsen et al.
[11] reported that MMP-13 expression by myofibroblasts
was often associated with microinvasive events, and they
proposed that MMP-13 may play an essential role during
the transition from ductal carcinoma in situ lesions to inva-
sive ductal carcinoma of the breast.
The POU class 1 homeobox 1 transcription factor
(POU1F1, also known as Pit-1) was originally described
in the pituitary gland, where it regulates cell differentiation
during organogenesis and acts as an activator for pituitary
gene transcription [12,13]. Pit-1 is also expressed in hu-
man breast [12]. Compared to normal breast, Pit-1 expres-
sion is higher in breast tumors, increases cell proliferation,
and regulates the expression of two breast cancer related
hormones, growth hormone (GH) and prolactin (PRL)
[14-16], which are also involved in both MMP regulation
and breast cancer metastasis [17,18]. In addition, Pit-1 over-
expression in a mouse xenograft tumor model promotes
tumor growth and metastasis in lung. Furthermore, elevated
Pit-1 expression in patients with breast cancer is positively
correlated with the occurrence of distant metastasis [19].
In the present study, we used human mammary cell
lines to analyze the regulation of MMP-1 and MMP-13
by Pit-1. In addition, we used immunodeficient mice to
evaluate the role of both metalloproteinases in Pit-1-
induced cancer invasiveness. Finally, we evaluated Pit-1,
MMP-1, and MMP-13 protein expression in 110 human
breast invasive ductal carcinomas.
Methods
Cell culture and reagents
The human breast adenocarcinoma cell lines MCF-7
and MDA-MB-231 were obtained from the European
Collection of Cell Cultures (ECCC, Salisbury, UK). These
cell lines were grown in 100-mm Petri dishes in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 100 U/ml penicillin, and
100 μg/ml streptomycin in an air-CO2 (95:5) atmosphere
at 37°C. Confluent cells were washed twice with phosphate-
buffered saline (PBS) and harvested by a brief incubation
with trypsin- ethylenediaminetetraacetic acid (EDTA)
solution (Sigma-Aldrich, St. Louis, MO, USA). Geneticin
(G418), culture medium, and sera were purchased
from Invitrogen Life Technologies, Carlsbad, CA, USA.
Immobilon-P membranes were from Millipore (Merck
Millipore, Billerica, MA, USA). Mytomycin C, MTT, puro-
mycin, and hygromycin B were from Sigma-Aldrich.
Plasmids and transfections
Transient transfection, Pit-1 knockdown, and stable
transfection of Pit-1 into MCF-7 cells were performed
as previously described [19,20]. The Pit-1-overexpressingMCF-7 cells were then transfected with pBABE-puro-Luc
vector and 48 hours later treated with 2.5 μg/μl of
puromycin to select clones (MCF-7-hPit-1-luc cells).
The shpLKO.1-MMP-1 and shpLKO.1-MMP-13 lentiviral
vectors containing two different short hairpin RNA
(shRNA) sequences for MMP-1 and MMP-13 were ob-
tained from Thermo Fisher Scientific (Waltham, MA,
USA) (see Additional file 1 and Figure S1A in Additional
file 2).
The pLKO.1-puro non-target shRNA control containing
a shRNA (shControl) was obtained from Sigma-Aldrich.
MCF-7-hPit-1-luc-shControl, MCF-7-hPit-1-luc-shMMP-
1 and MCF-7-hPit-1-luc-shMMP-13 cells were obtained
through infection with shControl, shMMP-1, and shMMP-
13 virus particles, respectively. Briefly, cell culture medium
was replaced by a medium without FBS and containing
5 μg/ml of polybrene.
After 4 hours, culture medium was again replaced
(DMEM plus 10% FBS), and lentiviral particles (Mission
pLKO.1-puro non-target shRNA, Mission-MMP-1
shRNA, and Mission MMP-13 shRNA transduction par-
ticles, Sigma-Aldrich) were added and incubated at 37°C
for 24 hours. Pit-1 knockdown was carried out using
two different Pit-1 small interfering RNA (siRNA) (Pit-1
siRNA-1 and Pit-1 siRNA-2), as previously described
(19). A scrambled siRNA was employed as control. Se-
quences of siRNAs are detailed in Additional file 1. The
proximal promoter regions of the human MMP-1 and
MMP-13 genes were synthesized by PCR and the prod-
uct subcloned into the Xho I and Hind III site of the
pGL2-basic plasmid (see Additional file 1). Site-directed
mutagenesis was performed with the QuikChange kit
from Stratagene (Agilent Technologies, Santa Clara, CA,
USA). The mutagenized oligonucleotide primers were as
follows (mutagenized bases on the sense strand are iden-
tified by lowercase letters): 5′-GATTGCCTAGTCT- AT
gacTAGCTAATCAAG-3′ and 5′-CCAGGACCCCTGtc-
gaCATCTTGAATGG-3′ for MMP-1 and MMP-13, re-
spectively. The newly constructed mutant plasmids were
designated pGL2-B-MMP-1-1633/-1MUT and pGL2-B-
MMP-13-145/+2MUT.
For luciferase assays, MCF-7 cells were transfected in 6-
well plates containing 6 μl of jetPEI Polyplus transfection
reagent (PolyPlusTransfection, Illkirch, France), 2 μg of
pRc-RSV or pRSV-hPit-1, 1 μg of each reporter plasmid,
and 50 ng of pRL-TK-Renilla (as transfection control) for
48 hours. The cells were lysed in buffer (100 μl lysis buffer,
Promega Corporation, Madison, WI, USA) and luciferase
activity was then measured in a Mithras LB 940 apparatus
(Berthold Technologies, Bad Wildbad, Germany).
RNA isolation and quantitative RT-PCR
Total RNA was isolated from the cell lines using TRIzol
(Invitrogen). cDNA was synthesized with Transcriptor
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Basel, Switzerland), and reactions of quantitative real-
time PCR were done using iQ SYBR Green Supermix
(Bio-Rad Laboratories, Alcobendas, Spain) on iCycler
equipment (7500 PCR Systems, Applied Biosystems,
Life Technologies, Carlsbad, CA, USA). The Pit-1, MMP-1,
MMP-13 and 18S samples were denatured at 94°C for 10
sec, annealed at 58, 59, 59 and 60°C, respectively, for 10 sec
and extended at 72°C for 10 sec, for a total of 33, 35, 35
and 30 cycles, respectively.
The samples were quantified using Sequence Detec-
tion Software 1.4 (Applied Biosystems), with 18S as
normalization control. The oligonucleotide sequences
are described in Additional file 1.
Cell proliferation (MTT) assay
Cell proliferation experiments were carried out using MTT
assay. MCF-7-hPit-1-luc cells, MCF-7-hPit-1-luc-shControl
cells, MCF-7-hPit-1-luc-shMMP-1 cells, or MCF-7-hPit-1-
luc-shMMP-13 cells (2.5 × 104 cells/ml) were seeded in a
volume of 0.5 ml in 24-well tissue culture plates. The ab-
sorbance of the samples was recorded 48 hours after
transfection at 590 nm in a multiwell plate reader (LB 940
Mithras, Berthold Technologies). Results were plotted as
the mean ± SD values of quadruplicates from at least two
independent experiments.
Western blot analysis
Western blotting was carried out as described elsewhere
[19]. Briefly, 60 μg of total protein was subjected to
SDS-PAGE electrophoresis. Proteins were transferred to
a nitrocellulose membrane, blocked, and immunolabeled
overnight at 4°C with a primary antibody (detailed in
Additional file 1). Then, the membrane was washed
three times with PBS-Tween-20, and incubated with the
appropriate secondary antibody for 1 hour. The signal
was detected with the Pierce enhanced chemilumines-
cence (ECL) Western blotting substrate (Thermo Fisher
Scientific, Rockford, IL, USA), and visualized by placing
the blot in contact with standard X-ray film. Relative
protein expression was quantified using the ImageJ soft-
ware (National Institutes of Health, Bethesda, MD, USA)
in at least three different blots, and values correspond to
mean values of fold-change in relation to beta-actin
values.
ChIP assay
Chromatin immunoprecipitation (ChIP) assays were
performed using the Upstate protocol as described pre-
viously [20]. Diluted soluble chromatin fractions were
immunoprecipitated with 1 μg polyclonal anti-Pit-1 anti-
body (Santa Cruz Biotechnologies, Heidelberg, Germany),
or control human immunoglobulin G (IgG) (Sigma-
Aldrich). The histone-DNA crosslinks were reversedby 4-hour incubation at 65°C. PCR was used to analyze
the DNA fragments from ChIP assays. Primer sequences
are detailed in Additional file 1.
Wound-healing and cell invasion assays
To perform the wound-healing assay, cells were seeded
in 60 mm plates and allowed to reach confluence.
Wounding was created using plastic pipette tip, and the
cells were serum starved and treated with mitomycin C
for 24 and 48 hours. Images were captured by an Olympus
DP72 camera (Olympus, Tokyo, Japan), and the distance
between the wound edges was measured. Cell invasion
assay was performed in BD BioCoat matrigel invasion
chambers according to the manufacturer’s instructions
(BD Biosciences, San Agustin de Gualix, Spain), as pre-
viously described [19]. Uncoated porous filters (8-μm
pore size) were used for estimating cell migration, and
matrigel-precoated filters were used for examining cell
invasion. Values for cell invasion were expressed as the
mean number of cells per field over four fields per filter
for triplicate experiments.
Animal studies
All animal studies were approved by the University of
Santiago de Compostela Ethics Committee for Animal
Experiments. Female mice (age matched, between 6
and 8 weeks) homozygous for the severe combined im-
mune deficiency (SCID) (CB17-Prkdcscid, Parc Research
Biomedica, Barcelona, Spain) were used for xenografting
studies.
Experimental metastasis assays were done as previ-
ously described [19]. Briefly, 1 × 106 MCF-7-hPit-1-luc
cells (n = 9, controls), MCF-7-hPit-1-luc-shControl cells
(n = 8, controls), MCF-7-hPit-1-luc-shMMP-1cells (n = 8),
or MCF-7-hPit-1-luc-shMMP-13 cells (n = 8) in 0.15 ml
of PBS and matrigel (50:50, BD Biosciences) were injected
into the mammary fat pad. At day 24 for control mice or
day 33 for MMP-1 and MMP-13 knockdown mice, ortho-
topic primary mammary tumors were measured (as de-
scribed below), and removed under anesthesia. Seventeen
days later (day 41 after cell injection for controls, and day
50 for MMP-1 and MMP-13 knockdown mice) mice were
sacrificed, and lungs removed and examined for metasta-
sis. Xenografts were visualized by luminescence at days 10
(all groups), 24 (Pit-1-overexpressed mice), and 33 (Pit-
1-overexpressed and MMP-1 or MMP-13 knockdown)
using the In Vivo Imaging System (IVIS, Caliper Life
Sciences, Alameda, CA, USA). An intensity map was ob-
tained using the Living Image software (Caliper Life Sci-
ences). The software uses a color-based scale to represent
the intensity of each pixel (ranging from blue for low to red
for high). Lung micrometastasis was explored in paraffin
sections by hematoxylin and eosin (H&E) staining and cyto-
keratin 7 (CK7) immunostaining. Immunohistochemistry
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Glostrup, Denmark). FLEX Ready-to-Use Primary Anti-
bodies to CK7, CK19, and ki-67 (Dako) were used. For de-
tection we used EnVision FLEX/HRP (Dako). The number
of metastatic foci was counted in lung after staining with
H&E and immunostaining with CK7, and the size of each
foci was evaluated by measuring its diameter (in μm)
using the Olympus DP-Soft morphometry program in an
Olympus DX51 microscope. For automated ki-67 scoring
the ACIS III (Automated Cellular Imaging Systems,
Dako-Agilent Technologies, Carpinteria, CA, USA) was
used. The ACIS III system scans the slide and is capable
of differentiating positive and negative nuclei. Six repre-
sentative areas were selected in each section and the
system generated an average score.
Patients and immunohistochemistry
One hundred and ten patients with invasive breast can-
cer (without distant metastasis at the time of initial diag-
noses) treated at Fundación Hospital de Jove of Gijón
(Spain), between 1990 and 2003, were selected based on
the availability of clinical history and a minimum 5-year
follow-up. The clinicopathological characteristics of
patients and their tumors are shown in Table S1 in
Additional file 3. Women were treated according to
our institutional guidelines. The study adhered to national
regulations and was approved by our regional Ethics and
Investigation Committee (Comité Ético de Investigación
Clínica Regional del Principado de Asturias). Breast car-
cinoma tissue samples were obtained at the time of sur-
gery. Prior informed consent was obtained from patients.
Routinely fixed (overnight in 10% buffered formalin),
paraffin-embedded tumor samples stored in our pathology
laboratories were used. Histopathologically representative
tumor areas without necrosis were defined on H&E-
stained sections. Serial 5-μm sections were consecutively
cut with a microtome (Leica Microsystems, Barcelona,
Spain) and transferred to adhesive-coated slides. Imunohis-
tochemistry was done on these sections using a TechMate
TM50 autostainer (Dako) as previously described [19]. A
polyclonal anti-Pit-1 (Santa Cruz Biotechnology), mono-
clonal anti-MMP-1 (NeoMarkers, Fremont, CA, USA)
and anti-MMP-13 (Santa Cruz Biotechnology) antibodies
were used. To enhance antigen retrieval, tissue sections
were treated in a PT-Link™ (Dako) at 97°C for 20 minutes,
in citrate buffer pH 6.1 for MMP-1 and in Tris-EDTA buf-
fer pH 9 for MMP-13, and then washed in PBS.
Endogenous peroxidase activity was blocked by incubat-
ing the slides in peroxidase-blocking solution (Dako) for
5 minutes. The EnVision Detection Kit (Dako) was used
as the staining detection system. Sections were counter-
stained with hematoxylin, dehydrated with ethanol, and
permanently coverslipped. For each antibody prepar-
ation, the location of immunoreactivity, percentage ofreactive area and intensity were determined. All cases
were semiquantified for each protein-stained area. An
image analysis system with the Olympus BX51 micro-
scope and soft analysis (analySIS™, soft imaging system)
were used as follows: tumor sections were stained with
antibodies according to the method explained above
and counterstained with hematoxylin. There were dif-
ferent optical thresholds for both stains. Each slide was
scanned with a 400X power objective and four fields
were selected per case to determine protein-reactive
areas. The computer program selected and traced a line
around antibody-reactive areas (higher optical thresh-
old: red spots), with the remaining, nonstained areas
(hematoxylin-stained tissue with lower optical thresh-
old) standing out as a blue background. Area ratios of
stained (red) versus nonstained (blue) were determined
for all fields. To evaluate immunostaining intensity we
used a numeric score from 0 to 3: 0 = no reactivity;
1 = weak reactivity; 2 =moderate reactivity; and 3 = intense
reactivity. Using an Excel spreadsheet, the score of one
field was obtained by multiplying the intensity score (I) by
the percentage of reactivity area (PA) (total score: I × PA).
In addition, for each tumor the mean score of the four
fields evaluated was calculated. We also evaluated the
immunohistochemical staining exclusively in cancerous
cells or in stromal cells (mononuclear inflammatory cells,
(MICs)- and fibroblast-like cells), and every evaluated field
contained at least 10 stromal cells. We considered immu-
nostaining to be positive when at least 10% of cells showed
positivity. We distinguished stromal cells from cancer cells
because the latter are larger in size, and because fibro-
blasts are spindle-shaped whereas mononuclear inflamma-
tory cells are rounded. Moreover, while cancer cells are
arranged forming either acinar or trabecular patterns,
stromal cells are spread.
Statistical analysis
Values are expressed as mean ± standard deviation
(SD). Means were compared using two-tailed Student’s
t test or one-way ANOVA, with the Tukey-Kramer
multiple comparison test for post hoc comparisons.
After analyzing the human tumor distribution of score
values by the Kolmogorov-Smirnov test, nonparamet-
ric methods were used to analyze the data. Immuno-
staining score values for each protein were expressed
as a median (range). Correlation between score values
was calculated by using the Spearman correlation test.
Comparison of immunostaining values between groups
was done with the Mann-Whitney or Kruskal-Wallis tests.
Statistical results were corrected applying Bonferroni’s
correction. P values of less than 0.05 were considered
statistically significant. The PASW Statistics 18 pro-
gram was used for all calculations (SPSS Inc, Chicago,
IL, USA).
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Pit-1 regulates MMP-1 and MMP-13 mRNA
and protein levels in MCF-7 and MDA-MB-231
cell lines
To evaluate the effect of Pit-1 on MMP-1 and MMP-13
mRNA expression, we carried out a real-time PCR. Pit-1
overexpression in MCF-7 cells using the pRSV-hPit-1
vector induced a significant increase in both MMP-1
(P <0.01) and MMP-13 (P <0.001) mRNA signal in re-
lation to controls (Figure 1A). Our data indicated that
Pit-1 overexpression increased MMP-1 and MMP-13
mRNA between two and three times, respectively.
Given that MMP protein levels in MCF-7 cell extracts
are low, MMP-1 and MMP-13 protein expression was
evaluated in MDA-MB-231 cells by Western blot.
Figure 1B shows increased and decreased MMP-1 and
MMP-13 protein expression after Pit-1 overexpression
and Pit-1 knockdown, respectively. Three different
blots were quantified by densitometry, and the results
are shown in Figure 1C.Figure 1 Pit-1 regulates MMP-1 and MMP-13 expression. (A) MCF
vector and 48 hours later a real-time PCR was carried out to evalua
of MMP-1, MMP-13, Pit-1 and β-actin in MDA-MB-231 cells 48 hours
quantitation of three different blots. Values expressed as mean ± SD represen
β-actin values. MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproRegulation of MMP-1 and MMP-13 by the Pit-1 transcription
factor at transcriptional level
Using the Transcription Element Search Software pro-
gram (TESS, University of Pennsylvania, Philadelphia,
PA, USA [21]), several putative Pit-1 binding sites
were found in the MMP-1 and MMP-13 promoter
(Figure 2A-C). To determine whether Pit-1 binds to
the MMP-1 and MMP-13 genes, a ChIP assay was car-
ried out using gene-specific primers (see Additional
file 1). Specific binding of Pit-1 to the A, B, and D sites of
the MMP-1 promoter was observed in pRSV-hPit-1-over-
expressed MCF-7 cells, indicating that Pit-1 binds to the
MMP-1 promoter gene in vivo (Figure 2B). A ChIP assay
was also carried out to evaluate Pit-1 binding to the
MMP-13 promoter (Figure 2D). Our data indicated
specific Pit-1 binding to regions A, B, C, D, and E in
the MMP-13 promoter, suggesting MMP-13 regulation by
Pit-1, such as occurs with the MMP-1 gene. Transfection
reporter assays (Figure 3A-B) indicate that Pit-1 transcrip-
tionally regulates the MMP-1 and the MMP-13 gene.-7 cells were transfected with the pRSV-hPit-1 overexpression
te MMP-1, MMP-13, and Pit-1 mRNA expression. (B) Western blot
after Pit-1 overexpression or Pit-1 knockdown. (C) Densitometric
t relative Pit-1, MMP-1, and MMP-13 protein expression in relation to
teinase-13; Pit-1, POU class 1 homeobox 1.
Figure 2 Pit-1 binds to the MMP-1 and MMP-13 promoter. (A)
Diagram of the human MMP-1 gene promoter showing the putative
Pit-1 binding sites, and the location of the primers used in the ChIP
assay. (B) Soluble chromatin prepared from control, pRc/RSV, or
pRSV-hPit-1-transfected MCF-7 cells were immunoprecipitated with
an anti-Pit-1 antibody or control IgG. The immunoprecipitated DNA
was amplified by PCR using primers (A, B, C, and D) that amplified
regions of the MMP-1 promoter with or without the putative Pit-1
binding sites. (C) Diagram of the human MMP-13 gene promoter
showing the putative Pit-1 binding sites, and the location of the primers
used in the ChIP assay. (D) Soluble chromatin and immunoprecipitation
were performed as described in B. The immunoprecipitated DNA was
amplified by PCR using primers (A, B, C, D, and E) that amplified regions
of the MMP-13 promoter. ChIP, chromatin immunoprecipitation; MMP-1,
matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13; Pit-1,
POU class 1 homeobox 1.
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that Pit-1 binds to a region comprised between −1633/-1
bp from the start transcription site and this region is
necessary for Pit-1-induced MMP-1 transcription. The
functionality of the proximal Pit-1 response element
was tested by mutation in the context of the pGL3B-
MMP-1-1633/-1 construct (see Additional file 1). Spe-
cifically, three different mutations were introduced intothe MMP-1-1633/-1 sequence at a position −104/-101
from the transcription start site (pGL3B-MMP-1-1633/-
1MUT). This construct was cotransfected into MCF-7
cells with the pRc/RSV or with the pRSV-hPit-1 vector.
As shown in Figure 3A, the response to Pit-1 was com-
pletely wiped out in cells transfected with the mutant
construct. Similarly, we also evaluated transcriptional
regulation of the MMP-13 promoter by Pit-1 using
several constructs containing specific deletions of the
pGL3B-MMP-13-1548/+2 construct. As observed in
Figure 3B, the response to Pit-1 overexpression in MCF-7
cells gradually decreased, depending on the size of the
MMP-13 promoter. Mutation of a Pit-1 binding site
in the position −35/-31 bp in the pGL2-B-MMP-13-
145/+2MUT construct (see Additional file 1) reduced
transcriptional activation as compared with the wild-type
construct (pGL2-B-MMP-13-145/+2). In summary, our
data suggest that Pit-1 regulates MMP-1 and MMP-13 ex-
pression by binding to their gene promoter region.
Knockdown of MMP-1 and MMP-13 reduces motility and
invasion in Pit-1-overexpressing cells
To evaluate the effect of MMP-1 and MMP-13 knock-
down on motility and invasion in MCF-7 cells with Pit-1
overexpression and in MDA-MB-231 cells with Pit-1
knockdown, we carried out wound-healing, migration,
and invasion assays. As previously demonstrated, Pit-1
induces a significant increase in MCF-7 cell migration
[19]. This was also observed in the present study, as
demonstrated by the absence of wound after Pit-1 overex-
pression (Figure 4A and Figure S2 in Additional file 4).
Knockdown of both MMP-1 and MMP-13 (two inde-
pendent hairpins) significantly (P <0.005) reduced cell mo-
tility in Pit-1-overexpressing MCF-7 cells (Figure 4A, and
Figure S2 in Additional file 4). In MDA-MB-231 cells,
which have higher basal Pit-1 expression levels than MCF-
7 cells, Pit-1 knockdown significantly reduced cell motility
(Figure 4B and Figure S3 in Additional file 5). However, in
Pit-1 knocked-down cells, neither MMP-1(1) and (2) nor
MMP-13(1) and (2) knockdown significantly modified
migration as compared to cells with MMP-1(1) and (2)
and MMP-13(1) and (2) knockdown alone (Figure 4B,
and Figure S3 in Additional file 5). We next explored
whether MMP-1 and MMP-13 knockdown affected mi-
gration and invasion in Pit-1-overexpressing MCF-7
cells in the matrigel invasion assay. Figures 4C-F shows
that knockdown of either MMP-1 or MMP-13 led to a
significant (P <0.0001) decrease in both migration and
invasion capacity of Pit-1-overexpressed MCF-7 cells, as
compared with only Pit-1-overexpressed MCF-7 cells.
We also studied the effect of MMP-1 and MMP-13
knockdown on three-dimensional growth. MDA-MB-
231 cells were cultured in matrigel, in which the cells
form spherical structures. However, reduced levels of
Figure 3 Deletion analysis identified a Pit-1-responsive region in the human MMP-1 and MMP-13 promoter. (A) The MMP-1 promoter
fragments that fused to the pGL2-Basic vector (pGL2B) were transfected into MCF-7 cells and then transfected with the pRc/RSV or the pRSV-hPit-1
vector. Normalized relative luciferase units (RLU) were calculated as the ratio of luciferase activity in the pRSV-hPit-1-transfected cells to that in the
corresponding control (pRc/RSV-transfected) cells. (B) The MMP-13 promoter fragments that fused to the pGL2Basic vector (pGL2B) were transfected
as indicated in A. Data are expressed as indicated in A. MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13; Pit-1, POU class 1
homeobox 1.
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dimensional growth of MDA-MB-231 cells, as compared
with control cells (Figure S1 B-C in Additional file 2).
MMP-13 knockdown in a xenograft mice model with Pit-1
overexpression blocked breast cancer invasiveness
It has been shown that MCF-7 cells present very low
levels of metastasis [22,23]. However, overexpression of
Pit-1 in this cell line significantly increases metastasis in
lung [19]. Therefore, we tested the potential to metastasize
in vivo of MCF-7 cells stably transfected with Pit-1 alone
or with Pit-1 and either MMP-1 or MMP-13 knockdown.
SCID female mice were injected in the mammary fat pad
with either MCF-7-hPit-1-luc cells (n = 9), MCF-7-hPit-1-
luc-shControl cells (n = 8), MCF-7-hPit-1-luc-shMMP-1
(1) cells (n = 8), or MCF-7-hPit-1-luc-shMMP-13(1) cells
(n = 8). Twenty-four days after MCF-7-hPit-1-luc and
MCF-7-hPit-1-luc-shControl cell injection, and 33 daysafter MCF-7-hPit-1-luc-shMMP-1 and -shMMP-13 injec-
tion, primary mammary tumors were excised under
anesthesia in both groups of animals (Figure 5A). Our
data indicated that knockdown of MMP-1 and MMP-13
reduced tumor growth in Pit-1-overexpressing mice.
In fact, tumor growth at day 10 was significantly
lower in mice injected with MCF-7-hPit-1-luc-shMMP-1
(P = 0.0011) and -shMMP-13 (P = 0.0013) cells as com-
pared to controls (Figure 5B). At day 24, considerable
tumor growth was observed in controls, while almost no
tumor growth was observed in MMP-1 and MMP-13
knockdown mice (data not shown). Even though tumors
in knockdown mice were allowed to continue growing
until day 33, only very slight growth was found (Figure 5B).
To evaluate why the growth of tumors in mice with Pit-1
overexpression was faster than in mice with Pit-1 overex-
pression plus MMP-1 or MMP-13 knockdown, we evalu-
ated the ki-67 proliferation marker expression in tumors
Figure 4 MMP-1 and MMP-13 knockdown reduces invasive features in MCF-7 cells with Pit-1 overexpression, and in MDA-MB-231 cells.
(A-B) Wound-healing assay in (A) MCF-7 cells with Pit-1 overexpression (pRSV-hPit-1), and knockdown of MMP-1 (shMMP-1(1) and shMMP-1(2))
and MMP-13 (shMMP-13(1) and shMMP-13(2)); (B) MDA-MB-231 cells with knockdown of Pit-1 (siPit-1), MMP-1 (shMMP-1(1) and shMMP-1(2)), and
MMP-13 (shMMP-13(1) and shMMP-13(2)). Distance between the wound edges was measured at 48 hours in three different assays, and data are
represented as mean ± SD; ns = not significant. (C-D) Cell motility through uncoated filters (migration) at 24 hours in control MCF-7 cells (pRcRSV),
Pit-1-overexpressing MCF-7 cells (pRSV-hPit-1), and Pit-1-overexpressing and knockdown of MMP-1 or MMP-13 MCF-7 cells (pRSV-hPit-1 +
shMMP-1 or −13). (E-F) Cell motility through matrigel-coated filters at 48 hours in control cells, cells transfected with the pRSV-hPit-1 vector,
and cells transfected with pRSV-hPit-1 and knockdown of MMP-1 (Pit-1 + shMMP-1) or MMP-13 (Pit-1 + shMMP-13). Numbers represent
mean ± SD. Scale bar: 100 μm. MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13; Pit-1, POU class 1 homeobox 1.
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tumors from mice injected with MCF-7-hPit-1-luc
and MCF-7-hPit-1-luc-shControl cells had a larger
proliferative area (high ki-67 expression, 83.6 ± 13.7%
and 93.0 ± 3.7%, respectively) and a larger necrotic area
than those injected with MCF-7-hPit-1-luc-shMMP-1
and -shMMP-13, which showed low ki-67 expression
(47.2 ± 19.6% and 36.2 ± 26.3%, respectively). This suggeststhat the small tumor size in MMP-1 and MMP-13 knock-
down mice could be due to low cell proliferation. An ex-
ample of whole tumor size stained with ki-67 is shown in
Figure S4A in Additional file 6. In addition, we carried out
an in vitro MTT assay using MCF-7 cells to evaluate cell
proliferation. Our data show a significant (P <0.001) de-
crease in cell proliferation at 48 hours in cells with Pit-1
overexpression and MMP-1 or MMP-13 knockdown as
Figure 5 Orthotopic injection of MCF-7 cells with Pit-1 overexpression and MMP-13 knockdown in SCID mice blocks metastasis to lung.
(A) Schematic representation of experimental induction of metastasis. At day 0, SCID mice were injected into the mammary fat pad either with
MCF-7 cells: (a) with Pit-1 overexpression (controls, n = 9), (b) with Pit-1 overexpression and shControl (controls, n = 8), (c) with Pit-1 overexpression and
MMP-1 knockdown (n = 8), and (d) with Pit-1 overexpression and MMP-13 knockdown (n = 8). At day 24 (in mice with Pit-1 overexpression and
shControl) or day 33 (in MMP-1 and MMP-13 knockdown mice), animals were anesthetized and breast tumors resected. Mice lived until day 41
(Pit-1 overexpression) or day 50 (Pit-1 plus MMP-1 or MMP-13 knockdown), and then were sacrificed and lungs removed for analysis. (B) Scatter
plots of tumor growth in SCID mice at days 10 (all groups), 24 (mice with Pit-1 overexpression, Pit-1, and Pit-1 + shControl), and 33 (mice with
Pit-1 overexpression and MMP-1 or MMP-13 knockdown), as described in A. Horizontal bars represent mean ± SEM. (C) ki67 immunostaining of
tumors from mice injected with MCF-7 and Pit-1 overexpression (Pit-1), Pit-1 + shControl, Pit-1 + shMMP-1, or Pit-1 + shMMP-13. NA: necrotic
area; HPA: high proliferative area; LPA: low proliferative area. Scale bar: 50 μm. (D) Five out of the nine mice with Pit-1 overexpression (day 41),
six out of the eight with Pit-1 overexpression and shControl (day 41), and four out of the eight with Pit-1 overexpression and MMP-1 knockdown (day
50) developed lung metastasis, while none of the eight mice with MMP-13 knockdown (day 50) showed micrometastasis in lung. (E) Representative
example of mice. Color indicates tumor cell luminescence. H&E staining and CK-7 and CK-19 immunopositivity in lung. Scale bar: 100 μm.
CK, cytokeratin; H&E, hematoxylin and eosin; MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13; Pit-1, POU class 1
homeobox 1; SCID, severe combined immunodeficiency.
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S4B in Additional file 6).
After excision of tumors, mice lived until day 41 (Pit-1
and Pit + shControl) and 50 (Pit-1 + shMMP-1 or
shMMP-13) after injection of MCF-7 cells. Mice were
then sacrificed and lungs were removed, fixed, paraffin-
embedded, sectioned, and stained with H&E and spe-
cific antibodies for immunohistochemistry analysis. Five
out of the nine mice injected with Pit-1-overexpressing
cells (controls), six out of the eight mice injected with
Pit-1-overexpressing cells + shControl, and four out of
the eight mice injected with Pit-1-overexpressing +
shMMP-1 transfected cells developed micrometastases
in lung, while none of the eight mice injected with the
MCF-7 cells transfected with the pTRE2-hPit-1-Luc-
shMMP-13 showed micrometastases in lungs (Figure 5D).
Micrometastases in lungs showed immunopositivity for
CK-7, and CK-19 (Figure 5E). These antibodies react only
with human and not with mouse cytokeratins. Neither size
(Pit-1: 166.2 ± 174.1 μm, Pit-1 + shControl: 183.7 ± 79.2
μm, and Pit-1 + shMMP-1: 185.5 ± 132.1 μm) nor number
of metastases (Table S2 in Additional file 7) were signifi-
cant among groups of mice.
Expression of both MMP-1 and MMP-13 correlates with
Pit-1 expression in human breast tumors
To further evaluate the clinical value of MMP-1, MMP-13
and Pit-1 expression in human breast tissue, these pro-
teins were analyzed by immunohistochemistry in 110 in-
vasive ductal carcinomas of the breast. Representative
examples of Pit-1, MMP-1 and MMP-13 immunostaining
in tumors are shown in Figure 6A. Pit-1 protein expres-
sion was detected mainly in the nuclei of tumor or control
epithelial cells, whereas MMP-1 and MMP-13 expression
had a cytoplasmic location in all positive cases. MMP-1
and MMP-13 expression was also evaluated in stromal
cells (that is fibroblasts, and mononuclear inflammatory
cells, MICs) and correlated with global Pit-1 expression.
Although Pit-1 expression was not quantified by cell
group, it was indeed observed in all three cell groups. An
example of Pit-1, MMP-1, and MMP-13 expression in
tumor and stromal cells is shown in Figure 6B. The per-
centage of positive cells for each protein was always higher
than 50% in positive case for each cell type. A total of 89
tumors (80.9%) stained positively for Pit-1, with clear
differences in intensity and percentage of stained cells.
MMP-1 expression was detected in 105 tumors (95.4%)
and MMP-13 in 84 tumors (76.4%). The median score
value was 35.4 (range 0 to 194.5) for Pit-1, 119 (0 to
206.2) for MMP-1, and 42 (0 to 135.8) for MMP-13.
Distribution of Pit-1, MMP-1 and MMP-13 score values
are shown in Figure S5 in Additional file 8. In relation
to global expression (score values) of Pit-1, MMP-1 and
MMP-13, our result showed a direct correlation betweenPit-1 score values and MMP-1 (r sub B = 0.242, P = 0.011)
and MMP-13 (r sub B = 0.199, P = 0.041) (Figure 6C). In
addition, we observed that MMP-1 and MMP-13 global
expression was higher in Pit-1-positive tumors compared
with Pit-1-negative tumors (median (range): MMP-1: 123.7
(0 to 206.2) vs. 60.4 (0 to 151.8), P = 0.014; MMP-13: 43.9
(0 to 135.8) vs. 0 (0 to 67.9), P = 0.034). A significant
positive correlation between Pit-1 and both MMP-1
and MMP-13 was also found in human breast tumor
datasets [24-26].
Our results also showed significant associations between
proteins in terms of cellular type. Score values of Pit-1
were significantly higher in tumors with MMP-1-positive
fibroblasts and MMP-13-positive fibroblasts than in tu-
mors with MMP-1-negative fibroblasts and MMP-13-
negative fibroblasts (P = 0.017 and P = 0.029, respectively)
(Table 1). Likewise, score values of Pit-1 were significantly
higher in tumors with MMP-1-positive cancerous cells
and MMP-13-positive cancerous cells than in tumors
with MMP-1- or MMP-13-negative cancerous cells
(P <0.001) (Table 1).
In addition, we evaluated the potential association be-
tween score values from Pit-1, MMP-1 and MMP-13
and relapse-free survival in all patients included in the
present study. The determination of optimal cutoff
values for Pit-1 and MMP-1 in breast tumors was done
for predicting recurrence. P values obtained for each
cutoff value are plotted against the value itself (Figure
S6A-B in Additional file 9). This statistical analysis showed
no significant association between score values of MMP-
13 and recurrence (data not shown). However, our data
showed that high score values for Pit-1 and MMP-1
were significantly associated with recurrence. This
analysis led us to define a score value of 22 for Pit-1
(χ 2 = 4.71, P = 0.03) and of 130 for MMP-1 (χ 2 = 6.52,
P = 0.011) as optimal cutoff points. These values identi-
fied 73 (66.4%) and 40 (36.4%) patients, respectively,
with a high probability of recurrence (Figure S6C-D in
Additional file 9). We also determined the relapse-free
survival curves for patients with breast carcinomas based
on the combination of these optimal cutoff points. Both
high Pit-1 and MMP-1 expression identified a patient
subgroup (n = 31, 28.2%) with the highest probability of
recurrence (P = 0.004) (Figure S6E in Additional file 9).
The relationship between Pit-1, MMP-13 expression
and prognosis was determined in MICs. Breast tumors
containing MICs that were positive for Pit-1 and
MMP13 (n = 24, 21.8%) had a high probability of recur-
rence (P = 0.010) (Figure S6F in Additional file 9).
Discussion
In this study we found that Pit-1 regulated MMP-1 and
MMP-13 in breast cancer cells at transcriptional level.
Our data indicated that knockdown of MMP-13 blocked
Figure 6 Pit-1 expression in human ductal invasive carcinomas of the breast positively correlates with MMP-1 and MMP-13 expression.
(A) Representative set of negative and positive (1+, 2+, and 3+) Pit-1, MMP-1, and MMP-13 immunodetection in human breast invasive ductal
carcinomas. Scale bar: 100 μm. (B) Representative figures of positive Pit-1, MMP-1, and MMP-13 expression in tumor cells (1), fibroblasts (2), and
mononuclear inflammatory cells (MIC, 3). (C) Plots of median score values of MMP-1 and MMP-13 as a function of Pit-1 score groups, and table with
the values of Spearman correlation test. n = 110 human breast tumors. MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13;
Pit-1, POU class 1 homeobox 1.
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Pit-1 overexpression. In addition MMP-1 and MMP-13
positive expression in fibroblasts and tumor cells is posi-
tively correlated with high Pit-1 score values in human
breast tumors.The role of Pit-1 in breast carcinogenesis has recently
been demonstrated [19]. Pit-1 overexpression in the
mammary fat pads of SCID mice is related with metasta-
sis in lung, and elevated levels of Pit-1 in node-positive
breast cancer patients are positively correlated with distant
Table 1 Relationships between MMP-1 and MMP-13
expression by each cell type and Pit-1 global expression
in 110 breast carcinomas
Factor N Pit-1 median (range) P value
MMP-1
Tumor cell 0.004
negative 5 5.6 (0 – 13.1)
positive 105 38.3 (0 – 194.5)
Fibroblast 0.017
negative 15 21.5 (0 – 89.6)
positive 95 27.4 (0 – 194.5)
MICs 0.068
negative 30 31.8 (0 – 124.5)
positive 80 36.7 (0 – 194.5)
MMP-13
Tumor cell 0.0001
negative 26 12.2 (0 – 135.6)
positive 84 45.1 (0 – 194.5)
Fibroblast 0.029
negative 60 32.5 (0 – 194.5)
positive 50 43.9 (0 – 143.2)
MICs 0.120
negative 82 33.8 (0 – 194.5)
positive 28 45.0 (0 – 132.3)
MMP-1, matrix metalloproteinase-1; MMP-13, matrix metalloproteinase-13;
Pit-1, POU class 1 homeobox 1; MICs: mononuclear inflammatory cells.
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sion levels were found in 36% of patients with invasive
ductal carcinoma of the breast [19]. However, the mech-
anism of Pit-1 metastasis induction is unknown. Given
that MMPs are key proteins involved in the metastatic
process, in the present study we evaluated the role of Pit-1
on the expression and biological activity of two collage-
nases, MMP-1 and MMP-13, whose role in several pro-
cesses of the metastatic disease is well known [3]. In the
MCF-7 and MDA-MB-231 human breast cancer cell lines,
we showed that Pit-1 regulates MMP-1 and MMP-13.
This regulation is carried out at transcriptional level, as
demonstrated by ChIP and luciferase reporter assays.
Knockdown of either MMP-1 or MMP-13 significantly re-
duced motility and invasion capacity of MCF-7 cells with
Pit-1 overexpression. These are relevant findings consider-
ing that MMP-1 and MMP-13 have exceptionally wide
substrate specificity when compared with other MMPs,
and because these molecules are implicated in the degrad-
ation of the connective stromal tissue and invasion of the
basement membranes, which are key actions in the meta-
static process. MMP-1 cleaves several components of the
extracellular matrix, including collagen type I (the princi-
pal component of the connective tissue), II, III, VII, VIII,and IX, aggrecan, as well as serine protease inhibitors, and
α2 macroglobulin [3,27]. MMP-13 efficiently degrades the
native helix of fibrillar collagens with preferential activity
on type II collagen [28,29]. However, MMP-13 is also able
to degrade several other extracellular matrix proteins
in vitro, including collagens type IV, X, and XIV; fibronec-
tin; tenascin; and fibrillin [30,31]. In addition, it has been
shown that MMP-13 plays a central role in the MMP acti-
vation cascade, both activating and being activated by
other MMPs (MMP-14, 2 or 3) [32].
In order to explore whether knockdown of each of
these MMPs could also modify the metastatic potential
of Pit-1-overexpressing MCF-7 cells in vivo, we evalu-
ated the effect of MMP-1 and MMP-13 knockdown in
an SCID mice tumor xenograft model. Our data indicated
that knockdown of either MMP-1 or MMP-13 reduced
cell proliferation, as demonstrated by the low ki-67 ex-
pression in tumors compared to controls. Probably as a
consequence of this, tumor growth was also decreased in
xenografts. This was previously demonstrated with MMP-
13 in the human squamous cell carcinoma xenografts
[33], and with MMP-1 in the human breast carcinoma cell
line MDA-MB-231 in the mammary fat pad xenograft
model [34], and recently in the MMP-1a knockout mouse,
which has significantly decreased lung tumor growth
and angiogenesis [35]. On the contrary, overexpression
of MMP-1 (in conjunction with other genes) in human
breast carcinoma cells increased xenograft growth rates
[5], and facilitated the assembly of new tumor blood
vessels, the release of tumor cells into the circulation,
and the breaching of lung capillaries by circulating tumor
cells to seed pulmonary metastasis [36]. In human pa-
tients, it has recently been demonstrated that MMP-1
expression by MICs from sentinel lymph nodes (SLNs)
was significantly associated with metastatic spread to
non-SLNs, suggesting that the degradation capacity of
MMP-1 in the extracellular matrix may be responsible
for promoting tumor spread via the lymph nodes [37].
Our data indicate that MMP-13 knockdown completely
blocked cancer cell invasiveness to lung, suggesting that
MMP-13 is a necessary mediator of Pit-1 induction of
breast metastasis to lung. This experimental finding could
be in line with previous clinical data indicating that
MMP-1 and MMP-13 seem to be related with different
metastatic profiles in breast cancer. Whereas MMP-13 ex-
pression (but not MMP-1 expression) was significantly
and independently associated with the occurrence of dis-
tant metastasis in breast cancer [7,38], MMP-1 expression
was strongly associated with the metastatic progression
across the axillary lymphatic system [37]. These data seem
to support the hypothesis that hematogenous metastasis
and regional lymph node metastasis are different pro-
cesses of tumor spread [39,40], which may require differ-
ent substrate-specific degradation.
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between global expression (score values) of Pit-1 and ei-
ther MMP-1 or MMP-13 expression in human primary
breast carcinomas. Nevertheless, the great complexity of
interactions between cancerous cells and stromal cells in
the context of these malignancies should be taken into ac-
count. Thus, for example, it has been described that
MMP-13 is produced by fibroblast-like cells located in the
stromal compartment of the breast cancer tissue [41],
whereas other studies have indicated that MMP-13 is
synthesized predominantly by epithelial tumor cells
[8,42]. In our study, both MMP-1 and MMP-13 expres-
sion was observed in all three cell types studied (tumor
cells, fibroblasts, and MICs), but we only found a sig-
nificant correlation between MMP-1 and MMP-13 posi-
tive expression and high Pit-1 levels in tumor cells and
fibroblasts. It is well known that tumor stroma play a
fundamental role in tumor growth, invasion and dissemin-
ation, and that fibroblasts are the prevailing component of
tumor stroma [7,43-45]. Thus, it is tempting to speculate
that high Pit-1 levels in fibroblasts from breast tumors
could induce increased MMP-1 and MMP-13 expression,
which in turn may increase collagen degradation and
facilitate the dissemination of tumor cells to lung.
However, only MMP-13 knockdown blocks dissemination
of Pit-1-overexpressing tumor cells to lung, suggesting
that MMP-13 mediates in this process.
In summary, our data indicates that Pit-1 increases
and activates MMP-1 and MMP-13 expression acting at
transcriptional level by binding to their promoters. In
mice, knockdown of MMP-13 blocks Pit-1-induced
breast cancer cell invasiveness induced by Pit-1. Finally,
in human breast tumors there is a significant correlation
between Pit-1 and MMP-1 and MMP-13 expression in
both tumor and fibroblast cells, suggesting a relationship
between Pit-1 and MMPs expression in Pit-1-induced me-
tastasis to lung.
Conclusions
Breast cancer is a heterogeneous illness that encompasses
several distinct disease entities, often referred to intrinsic
subtypes of breast cancer. It has previously been demon-
strated that patients with breast cancer and overexpres-
sion of the Pit-1 transcription factor are associated with
higher occurrence of distant metastasis, but the mecha-
nisms remain unknown. The present study demonstrates
that Pit-1 increases MMP-1 and MMP-13 expression at
transcriptional level. Given that these MMPs have been
related to breast cancer metastasis, we explored the effect
of Pit-1 overexpression and MMP-1 or MMP-13 knock-
down in an SCID mouse xenograft tumor model. Both
Pit-1 overexpression and Pit-1 overexpression together
with MMP-1 knockdown induced metastasis in lung.
On the other hand, Pit-1 overexpression and MMP-13knockdown completely blocked breast cancer invasive-
ness to lung. We further showed that Pit-1 positively
correlated with MMP-1 and MMP-13 expression in
110 human breast tumors, and positive Pit-1 expression
also correlated with positive expression of MMP-1 and
MMP-13 in tumor cells and fibroblasts. Taken together,
our data point to MMP-13 as a target in breast tumors
with Pit-1 overexpression.Additional files
Additional file 1: Supplementary methods (plasmids and
transfections, siRNAs, ChIP assay, real-time PCR, antibodies).
Additional file 2: Figure S1. Effect of MMP-1 or MMP-13 knockdown
on three-dimensional (3D) growth in MDA- MB-231 cell culture. (A)
MMP-1 and MMP-13 protein expression after MMP-1 and MMP-13
knockdown. MDA-MB-231 cells were transfected with MMP-1 shRNA
(1), MMP-1 shRNA (2), MMP-13 shRNA (1) and MMP-13 shRNA (2) and
48 hours later protein extracts were evaluated by Western blot. (B-C)
Three-dimensional (3D) growth of MDA-MB-231 cells after MMP-1 and
MMP-13 knockdown. MDA-MB-231 cells transfected with missense
control shRNA, or shMMP-1 (B) or shMMP-13 (C) were cultured in
solidified matrigel for 10 days and phase contrast photographs of cells
as monolayers or in three-dimensional (3D) cultures were taken with
an Olympus DP72 camera. The quantitation of sphere diameter was
performed manually by tracing a straight line across the diameter of the
sphere and scoring its value as arbitrary length units. Scale bar: 75 mm.
Additional file 3: Table S1. Basal characteristics of 110 patients with
invasive ductal carcinoma of the breast.
Additional file 4: Figure S2. Wound healing was carried out in MCF-7
cells with Pit-1 overexpression (pRSV-hPit-1), and knockdown of MMP-1
(shMMP-1(1) and shMMP-1(2)) and MMP-13 (shMMP-13(1) and shMMP-13
(2)). Wounding was done using plastic pipette tip. At 24 and 48 hours,
the distance between the wound edges was measured. Images were
captured with an Olympus DP72 camera. Scale bar: 150 μm.
Additional file 5: Figure S3. Wound healing was carried out in
MDA-MB-231 cells with Pit-1 knockdown (siPit-1), and knockdown of
MMP-1 (shMMP-1(1) and shMMP-1(2)) and MMP-13 (shMMP-13(1) and
shMMP-13(2)). Wounding was done using plastic pipette tip. At 24 and 48
hours, the distance between the wound edges was measured. Images were
captured with an Olympus DP72 camera. Scale bar: 150 μm.
Additional file 6: Figure S4. MPP-1 and MMP-13 knockdown reduces
tumor size. (A) Photos of slides showing tumors size at day 24 (in mice
with Pit-1 overexpression, Pit-1, and Pit-1 + shControl) or day 33 (in mice
injected with MCF-7-hPit-1-luc-shMMP-1 cells, or MCF-7-hPit-1- luc-shMMP-13
cells, Pit-1 + shMMP-1 and Pit-1shMMP-13, respectively), and immunostained
with ki-67. Scale bar: 1 cm. (B) Cell proliferation (MTT) assay in MCF-7 control
cells, MCF-7-hPit-1-luc cells, MCF-7-hPit-1-luc-shControl cells, MCF-7-hPit-1-
luc-shMMP-1 cells, and MCF-7-hPit-1-luc-shMMP-13 cells. The absorbance of
the samples was measured 48 h after transfection. Results were plotted as
the mean ± SD values of quadruplicates from at least two independent
experiments.
Additional file 7: Table S2. MMP-13 but not MMP-1 knockdown blocks
metastasis in lung. (A) Number of metastasis in lung at day 41 (in MCF-7-hPit-
1-luc- and MCF-7-hPit-1-luc-shControl-injected mice) or day 50 (in MCF-7-hPit-
1-luc-shMMP-1-injected mice). Number was quantified after CK7 staining. Size
represents mean + SD of total metastasis measurements. (B) Size (diameter in
μm of each metastasis) and number of metastasis (specified for each mice)
was evaluated using the Olympus DP-Soft morphometry program in an
OlympusDX51 microscope.
Additional file 8: Figure S5. Distribution score values obtained by
immunohistochemical staining of Pit-1, MMP-1, and MMP-13 in 110
invasive ductal carcinomas of the breast.
Sendon-Lago et al. Breast Cancer Research  (2014) 16:505 Page 14 of 15Additional file 9: Figure S6. Determination of cutoff values and their
relationship with biochemical recurrence. Maximum likelihood determination
of (A) Pit-1 and (B) MMP-1 cutoff values for predicting biochemical recurrence
in 110 patients with breast cancer. The values obtained for each cutoff value
are plotted against the value itself. Statistical significance is indicated by the
horizontal line at 0.05. Analysis led to the definition of 22 for Pit-1 (χ 2 = 4.71,
P= 0.03) and 130 for MMP-1 (χ 2 = 6.52, P= 0.011) as the optimal cutoff points.
Probability of relapse-free survival as a function of the optimal cutoff
point for (C) Pit-1 score values (P = 0.03), (D) MMP-1 (P = 0.011), and
(E) the combination of both cutoff points (P = 0.004). (F) Probability of
relapse-free survival as a function of Pit-1 and MMP-13 expression by
inflammatory mononuclear cells.
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